Details
Stereochemistry | RACEMIC |
Molecular Formula | C12H16F3N |
Molecular Weight | 231.2573 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCNC(C)CC1=CC(=CC=C1)C(F)(F)F
InChI
InChIKey=DBGIVFWFUFKIQN-UHFFFAOYSA-N
InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3
Molecular Formula | C12H16F3N |
Molecular Weight | 231.2573 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:10:04 UTC 2023
by
admin
on
Fri Dec 15 15:10:04 UTC 2023
|
Record UNII |
2DS058H2CF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
584217
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
||
|
NCI_THESAURUS |
C29728
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
||
|
WHO-VATC |
QA08AA02
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
||
|
WHO-ATC |
A08AA02
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
||
|
DEA NO. |
1670
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3337
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
D005277
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
4328
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | RxNorm | ||
|
100000081293
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
5220-89-3
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
SUPERSEDED | |||
|
1150
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
3080
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
C81418
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
FENFLURAMINE
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
2DS058H2CF
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
1596
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
5000
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
2DS058H2CF
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
CHEMBL87493
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
4613
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
458-24-2
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
207-276-3
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
SUB07561MIG
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
DB00574
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | |||
|
25990-46-9
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
SUPERSEDED | |||
|
m5274
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID4023044
Created by
admin on Fri Dec 15 15:10:04 UTC 2023 , Edited by admin on Fri Dec 15 15:10:04 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
OFF-TARGET->AGONIST |
5-HT2B receptors, which were subsequently identified as the target for cardiac valvulopathy and pulmonary hypertension. Release of serotonin leads to 5-HT2B signaling.
|
||
|
TARGET -> AGONIST |
STIMULATES THE RELEASE OF SEROTONIN RESULTS IN APPETITE SUPPRESSION; LEAD TO 6-16 FOLD INCREASE IN SEROTONIN IN THE HYPOTHALMUS
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
STIMULATES SEROTONIN RELEASE.
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Percent of dose excreted in urine as metabolite.
AMOUNT EXCRETED
URINE
|
||
|
METABOLITE TOXIC -> PARENT |
Responsible for
MAJOR
|
||
|
METABOLITE -> PARENT |
Metabolite to parent drug ratio in non-uraemic human plasma.
A positive correlation exists between plasma norfenfluramine levels and weight loss in man.
METABOLITE TO PARENT DRUG RATIO
PLASMA; URINE
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|